Skip to main content
    T

    Tango Therapeutics Inc (TNGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $24.17
    -1.33 (-5.22%)

    Market Cap: $4.32B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tango Therapeutics Inc (TNGX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Tango Therapeutics reported revenue of $62.38M for the fiscal year ended Dec 31, 2025, up 48.3% from the year before. That year, net income was -$101.59M with a net margin of -162.9%, operating cash flow was -$138.89M and free cash flow was -$139.93M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$68.39M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue grew from $24.65M, a compound annual rate of 16.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$62.38M+48.3%100.0%-178.4%-162.9%
    Dec 2024$42.07M+15.2%100.0%-346.1%-309.7%
    Dec 2023$36.53M+46.9%100.0%-312.6%-278.5%
    Dec 2022$24.86M-32.9%100.0%-446.8%-435.1%
    Dec 2021$37.04M+383.8%100.0%-157.1%-157.2%
    Dec 2020$7.66M-68.9%100.0%-681.8%-678.8%
    Dec 2019$24.65MN/A-30.9%-61.5%-57.2%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$62.38M$42.07M$36.53M$24.86M$37.04M$7.66M$24.65M
    Cost of revenue$0$0$0$0$0$0$32.27M
    Gross profit$62.38M$42.07M$36.53M$24.86M$37.04M$7.66M-$7.63M
    Research and development$132.16M$143.92M$115.20M$105.91M$77.64M$49.99M$32.27M
    Operating income-$111.29M-$145.59M-$114.17M-$111.07M-$58.19M-$52.20M-$15.16M
    Net income-$101.59M-$130.30M-$101.74M-$108.18M-$58.23M-$51.97M-$14.10M
    EBITDA-$104.94M-$135.49M-$105.81M-$107.97M-$57.54M-$51.36M-$14.52M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$53.81M$3.18M$5.39M$4.12M$11.61M$19.88M$6.47M$5.43M
    Gross profit$0$0$0-$479.00K$53.81M$3.18M$5.39M$4.12M$11.61M$19.88M$6.47M$5.43M
    Operating income-$78.12M-$59.78M-$48.77M-$41.86M$14.07M-$40.97M-$42.53M-$40.91M-$32.88M-$29.55M-$42.26M-$35.01M
    Net income-$68.39M-$55.34M-$45.51M-$38.75M$15.88M-$38.85M-$39.88M-$37.67M-$29.17M-$25.55M-$37.91M-$30.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.74M by $109.54M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$398.69M$316.49M$402.57M$436.47M$500.15M$207.25M$55.76M
    Current assets$353.76M$266.34M$346.54M$375.27M$492.34M$193.63M$41.66M
    Cash and equivalents$112.28M$69.53M$66.39M$59.97M$142.75M$28.38M$22.89M
    Total liabilities$52.51M$116.97M$149.46M$186.99M$155.41M$168.65M$47.86M
    Short-term debt$2.74M$2.45M$2.08M$1.77M$1.50M$959.00K$655.00K
    Shareholder equity$346.18M$199.52M$253.11M$249.48M$344.75M$38.60M$7.91M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.03B$1.07B$435.79M$398.69M$210.14M$237.89M$274.31M$316.49M$352.42M$381.45M$406.22M$402.57M
    Total liabilities$53.29M$49.35M$44.29M$52.51M$50.10M$102.94M$107.55M$116.97M$123.25M$133.78M$141.77M$149.46M
    Cash and equivalents$86.83M$345.56M$157.83M$112.28M$58.34M$39.27M$58.43M$69.53M$53.15M$51.57M$61.16M$66.39M
    Shareholder equity$980.17M$1.02B$391.51M$346.18M$160.03M$134.95M$166.76M$199.52M$229.17M$247.67M$264.45M$253.11M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$138.89M-$131.50M-$117.98M-$109.08M-$59.53M$70.07M-$24.80M
    Capital expenditures$1.05M$754.00K$1.53M$7.69M$1.84M$1.11M$1.82M
    Free cash flow-$139.93M-$132.25M-$119.51M-$116.77M-$61.36M$68.97M-$26.62M
    Share repurchases$36.00K$0$241.00K$8.00KN/AN/AN/A
    Investing cash flow-$40.87M$86.13M$41.43M$26.40M-$183.43M-$145.47M$848.00K
    Financing cash flow$222.50M$47.66M$82.41M$1.61M$357.32M$80.88M$11.00M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$37.14M-$38.87M-$44.36M-$29.72M-$30.95M-$36.52M-$41.70M-$36.65M-$33.39M-$23.61M-$37.86M-$27.47M
    Capital expenditures$77.00K$20.00K$2.00K$222.00K$151.00K$624.00K$51.00K$124.00K$115.00K$320.00K$195.00K$226.00K
    Free cash flow-$37.22M-$38.89M-$44.36M-$29.94M-$31.10M-$37.14M-$41.75M-$36.77M-$33.51M-$23.93M-$38.05M-$27.69M
    Last 12 quarters

    Frequently Asked Questions About TNGX

    What is Tango Therapeutics' annual revenue?

    Tango Therapeutics reported revenue of $62.38M for the fiscal year ended Dec 31, 2025.

    How fast is Tango Therapeutics' revenue growing?

    Revenue was up 48.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 35.9%.

    Is Tango Therapeutics profitable?

    No. Tango Therapeutics reported net income of -$101.59M for the fiscal year ended Dec 31, 2025, with a net margin of -162.9%.

    How much free cash flow does TNGX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$138.89M minus capital expenditures of $1.05M produced free cash flow of -$139.93M.

    How much debt does Tango Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.74M and cash and equivalents of $112.28M.